Implications of Comorbidity on Costs for Patients With Alzheimer Disease
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
BACKGROUND: No prior studies have used a comprehensive clinical classification system to examine the effect of differences in overall illness burden and the presence of other diseases on costs for patients with Alzheimer disease (AD) when compared with demographically matched nondemented controls. STUDY DESIGN: Of a total of 627,775 enrollees who were eligible for medical and pharmacy benefits for 2003 and 2004 in the MarketScan Medicare Supplemental and Coordination of Benefits Database, we found 25,109 AD patients. For each case, 3 demographically matched nondemented controls were selected using propensity scores. Applying the diagnostic cost groups (DCGs) model to all enrollees, 2003 diagnoses were used to estimate prospective relative risk scores (RRSs) that predict 2004 costs from all illness other than AD. RRSs were then used to control for illness burden to estimate AD's independent effect on costs. RESULTS: Compared with the control group, the AD cohort has more comorbid conditions (8.1 vs. 6.5) and higher illness burden (1.23 vs. 1.04). Individuals with AD are more likely to have mental health conditions, neurologic conditions, cognitive disorders, cerebrovascular disease, diabetes with acute complications, and injuries. Annual costs for AD patients are $3567 (34%) higher than for controls. Excess costs attributable to AD, after controlling for non-AD illness burden, are estimated at $2307 per year with outpatient pharmacy being the key driver ($1711 in excess costs). CONCLUSIONS: AD patients are sicker and more expensive than demographically matched controls. Even after adjusting for differences in illness burden, costs remain higher for AD patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alzheimer Disease in the US Population: Prevalence Estimates Using the 2000 Census
Hebert, L. E., Scherr, P. A., Bienias, J. L., Bennett, D. A., & Evans, D. A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.8.1119 · Cited by 2,168 · cited 1×
“(Med Care 2008;46: 839–846) Alzheimer disease (AD) is a devastating neurodegenerative disease affecting 1 in 10 individuals over 65 and nearly half of those over 85.(1,2) As the population ages, the prevalence of AD will increase.”
BackgroundOwnby, R. L., Crocco, E., Acevedo, A., John, V., & Loewenstein, D. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.5.530 · Cited by 1,493
McGeer, P. L., Schulzer, M., & McGeer, E. G. (1996) · Neurology · doi:10.1212/wnl.47.2.425 · Cited by 1,367
Lindsay, J. (2002) · American Journal of Epidemiology · doi:10.1093/aje/kwf074 · Cited by 1,261
Evans, D. A. (1989) · JAMA · doi:10.1001/jama.1989.03430180093036 · Cited by 1,226 · cited 1×
“(Med Care 2008;46: 839–846) Alzheimer disease (AD) is a devastating neurodegenerative disease affecting 1 in 10 individuals over 65 and nearly half of those over 85.(1,2) As the population ages, the prevalence of AD will increase.”
BackgroundDepression as a Risk Factor for Alzheimer Disease: The MIRAGE Study
Green, R. C., Cupples, L. A., Kurz, A., Auerbach, S., Go, R., Sadovnick, D., Duara, R., Kukull, W. A., Chui, H., Edeki, T., et al. (2003) · Archives of Neurology · doi:10.1001/archneur.60.5.753 · Cited by 551
Chen, P., Ganguli, M., Mulsant, B. H., & DeKosky, S. T. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.3.261 · Cited by 327
Depressive Symptoms and Cognitive Decline in Late Life: A Prospective Epidemiological Study
Ganguli, M., Du, Y., Dodge, H. H., Ratcliff, G. G., & Chang, C.-C. H. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.2.153 · Cited by 314
Alzheimer’s disease and related dementias increase costs of comorbidities in managed Medicare
Hill, J. W., Futterman, R., Duttagupta, S., Mastey, V., Lloyd, J. R., & Fillit, H. (2002) · Neurology · doi:10.1212/wnl.58.1.62 · Cited by 181
Cited by
The worldwide economic impact of dementia 2010
Wimo, A., Jönsson, L., Bond, J., Prince, M., Winblad, B., & International, A. D. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.11.006 · Cited by 1,141
The cost of Alzheimer's disease in China and re‐estimation of costs worldwide
Jia, J., Wei, C., Chen, S., Li, F., Tang, Y., Qin, W., Zhao, L., Jin, H., Xu, H., Wang, F., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.12.006 · Cited by 752
Comorbidity and dementia: a scoping review of the literature
Bunn, F., Burn, A.-M., Goodman, C., Rait, G., Norton, S., Robinson, L., Schoeman, J., & Brayne, C. (2014) · BMC Medicine · doi:10.1186/s12916-014-0192-4 · Cited by 451
“prevalence of comorbid medical conditions and related complaints [2-5].”
BackgroundCalderón‐Larrañaga, A., Vetrano, D. L., Ferrucci, L., Mercer, S. W., Marengoni, A., Onder, G., Eriksdotter, M., & Fratiglioni, L. (2019) · Journal of Internal Medicine · doi:10.1111/joim.12843 · Cited by 408
El-Hayek, Y. H., Wiley, R. E., Khoury, C. P., Daya, R. P., Ballard, C., Evans, A. R., Karran, M., Molinuevo, J. L., Norton, M., & Atri, A. (2019) · Journal of Alzheimer's Disease · doi:10.3233/jad-190426 · Cited by 216
“Moreover, most patients in the dementia stages of ADRD are elderly and typically suffer from comorbidities, such as cerebrovascular disease, albeit at a higher rate compared to individuals without ADRD [39, 40].”
Background
Metadata
- Authors
- Kuo, T.-C., Zhao, Y., Weir, S., Kramer, M. S., & Ash, A. S.
- Venue
- Medical Care
- Published
- 2008-08
- Volume
- 46
- Issue
- 8
- Pages
- 839-846
- ISSN
- 0025-7079 (ISSN-L)
- OpenAlex
- W2075058893
- Cited by
- 88
- References
- 9
- FWCI
- 3.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Implications of Comorbidity on Costs for Patients With Alzheimer Disease. https://app.cochat.ai/papers/10.1097/mlr.0b013e318178940b
- The paper
- Kuo, T.-C., Zhao, Y., Weir, S., Kramer, M. S., & Ash, A. S. (2008). Implications of Comorbidity on Costs for Patients With Alzheimer Disease. Medical Care. https://doi.org/10.1097/mlr.0b013e318178940b
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.